Key Dates

Related Announcements

RFA-CA-23-002  - Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to change the Application Due Date and correct the Budget Submission requirement for RFA-CA-23-002 " Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)". 

Part 1. Overview Information, Key Dates

Currently it reads:

Corrected to read (in italics):

 Part 2. Full Text of Announcement, Section IV. Application and Submission Information

Currently it reads:

R&R Budget

All instructions in the SF424 (R&R) Application Guide must be followed.

For this specific FOA, a modular budget is expected unless the applicant is a Foreign Organization.

Corrected to read (in italics):

All instructions in the SF424 (R&R) Application Guide must be followed.

All other aspects of RFA-CA-23-002 remain unchanged.

Inquiries

Please direct all inquiries to:

Scientific/Research Contact(s)

Kelly Crotty, Ph.D.
National Cancer Institute (NCI)
Telephone: 240-760-7997
Email: [email protected]

Tony Dickherber, Ph.D.
National Cancer Institute (NCI)
Telephone: 301-547-9980
Email: [email protected]

Financial/Grants Management Contact(s)

Sean Hine
National Cancer Institute (NCI)
Telephone: 240-276-6291
E-mail: [email protected]